Floatz logo

Iparomlimab

CTLA4

Guangzhou Medical UniversityPhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the CTLA4 cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Guangzhou Medical University
Phase 1/2CC
ETOPOSIDE
Guangzhou Medical University
Phase 1/2CC
Carboplatin
Guangzhou Medical University
Phase 1/2CC
TIL
Second Affiliated Hospital of Guangzhou Medical University
Phase 1CC

Same molecule, other indications

Iparomlimab is also rated in:

HCC - Hepatocellular CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
ES-SCLCDormant
BB
Indicative ·
70 / 100
View asset →
CTLA-4Dormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →